ANDA 62372, held by Bayer Pharms. Mezlocillin Sodium Monohydrate.
As of Nov 21, 2026, ANDA 62372 (Mezlin), held by Bayer Pharms, was not approved, with 0 approved supplements and 0 published complete response letters.
| MezlinEQ 2GM BASE/VIAL ยท injectable;injection | Mezlocillin Sodium Monohydrate | Discontinued |
| MezlinEQ 3GM BASE/VIAL ยท injectable;injection | Mezlocillin Sodium Monohydrate | Discontinued |
| MezlinEQ 4GM BASE/VIAL ยท injectable;injection | Mezlocillin Sodium Monohydrate | Discontinued |
| MezlinEQ 20GM BASE/VIAL ยท injectable;injection | Mezlocillin Sodium Monohydrate | Discontinued |
| MezlinEQ 1GM BASE/VIAL ยท injectable;injection | Mezlocillin Sodium Monohydrate | Discontinued |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. โWhat FDA's review saysโ is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters